Older adults and people with certain medical conditions are more likely to receive the respiratory syncytial virus (RSV) ...

Pfizer (NYSE:PFE) recently saw the European Commission expand the authorization for its RSV vaccine, ABRYSVO, to include ...

Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...

The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...

Pfizer’s RSV vaccine Abrysvo receives European approval to help protect adults aged 18-59 against RSV lower respiratory tract disease: New York Wednesday, April 2, 2025, 09:00 H ...

COVID, flu and RSV levels have already hit their peaks. (Pollen levels and springtime allergies are a whole different story.) ...

The bivalent respiratory syncytial virus prefusion F vaccine is highly effective and well tolerated against RSV-associated ...

Pfizer’s respiratory syncytial virus (RSV) vaccine has been approved by the European Commission (EC) to prevent ...

Pfizer has won European Commission expanded approval of its Abrysvo vaccine for respiratory syncytial virus, or RSV, for use in all adults. The New York drugmaker on Tuesday said the extended ...

The Royal Australian College of GPs (RACGP) has thrown its support behind South Australia's infant RSV immunisation program. Respiratory syncytial ...

For the first time, RSV immunisation is now available to Western Australians both during pregnancy, and for eligible babies ...

Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing ...